MANUEL GARMENDIA: Open Payments
NPI 1437624103 · SAN LUIS OBISPO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,106 in 49 payments from 15 companies in 2025. Trend: 2023 $786 · 2024 $817 · 2025 $1,106
Food & beverage: $1,021Education: $85
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $247 |
| Sumitomo Pharma America, Inc. | 8 | $148 |
| ABBVIE INC. | 7 | $136 |
| Procept Biorobotics Corporation | 1 | $118 |
| Astellas Pharma US Inc | 4 | $88 |
| Antares Pharma, Inc. | 3 | $72 |
| BLUEWIND MEDICAL | 3 | $70 |
| PFIZER INC. | 2 | $52 |
| UROGEN PHARMA, INC. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
Products named: ERLEADA, GEMTESA, Xtandi, AQUABEAM ROBOTIC SYSTEM, LUPRON DEPOT, XYOSTED, REVI, BOTOX.
Industry payments across CA — which companies pay providers there.
